It’s Time to End Drug-Resistant Tuberculosis
13 May 2019
Tuberculosis (TB) is an ancient disease that has killed over 2 billion people in the past 200 years. More recently, drug-resistant strains of TB which are resistant to one or more of the drugs normally used to treat it have emerged and spread. Drug-resistant TB (DR-TB) is the only major airborne drug-resistant epidemic. It is harder and more costly to treat than drug-susceptible TB (DSTB), and affects more than half a million people across the globe annually, mostly in low and middle income countries.
Further reading: The Economist Intelligence Unit
Healthy Animals
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Global Ambassador Network
Welcome at the AMR Insights Ambassador Network!
The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).
